Ocrelizumab (Ocrevus) has been granted US FDA approval for the treatment of both replacing-remitting MS (RRMS) and primary progressive MS (PPMS).  Ocrelizumab is a monoclonal antibody that targets and depletes B cells in the body.  It is the first therapeutic to have delivered successful clinical trial results for people with PPMS.  This is a significant landmark in the treatment of multiple sclerosis and will hopefully provide help to people living with PPMS.

For more information about Ocrelizumab (Ocrevus), use the following links:

MStranslate Summaries of Ocrelizumab (Ocrevus) Clinical Trial Results:

Website: http://www.mstranslate.com.au/ocrelizumab-primary-progressive-multiple-sclerosis/

YouTube: https://www.youtube.com/watch?v=2c8ZOUz4nlI

US FDA Approval Notice:

Website: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm549325.htm

New York Times Coverage:

Website: https://www.nytimes.com/2017/03/28/health/fda-drug-approved-multiple-sclerosis-ocrevus.html?_r=0

MStranslate will continue to provide updated information as it is released.

Leave a Reply

Your email address will not be published.